m
Recent Posts
Connect:
Thursday / May 26.
HomeTwitterJefferies Managing Dir. Michael Yee on $MRNA: “The overly high expectations and significant valuation is going to lead to challenges in 2022, and I think there’s going to be a lot of money flow out of this name as people digest what’s next for the company beyond COVID vaccines.”

Jefferies Managing Dir. Michael Yee on $MRNA: “The overly high expectations and significant valuation is going to lead to challenges in 2022, and I think there’s going to be a lot of money flow out of this name as people digest what’s next for the company beyond COVID vaccines.”